Bellevue Group AG Increases Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)

Bellevue Group AG lifted its position in Sage Therapeutics, Inc. (NASDAQ:SAGE) by 27.1% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,465,544 shares of the biopharmaceutical company’s stock after buying an additional 952,193 shares during the period. Sage Therapeutics makes up about 1.3% of Bellevue Group AG’s investment portfolio, making the stock its 22nd biggest position. Bellevue Group AG owned approximately 7.42% of Sage Therapeutics worth $83,684,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of SAGE. Lazard Asset Management LLC bought a new stake in Sage Therapeutics during the first quarter valued at approximately $127,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Sage Therapeutics by 353.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,937 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 5,406 shares in the last quarter. ProShare Advisors LLC lifted its position in Sage Therapeutics by 9.0% during the first quarter. ProShare Advisors LLC now owns 13,713 shares of the biopharmaceutical company’s stock valued at $257,000 after purchasing an additional 1,130 shares in the last quarter. Quest Partners LLC bought a new stake in Sage Therapeutics during the fourth quarter valued at about $261,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in Sage Therapeutics by 31.9% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,256 shares of the biopharmaceutical company’s stock worth $266,000 after buying an additional 2,967 shares in the last quarter. Institutional investors own 99.22% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. TD Cowen lowered their price objective on Sage Therapeutics from $30.00 to $16.00 and set a “buy” rating on the stock in a research report on Thursday, April 18th. Mizuho lowered their price target on shares of Sage Therapeutics from $18.00 to $16.00 and set a “neutral” rating on the stock in a report on Friday, July 19th. Needham & Company LLC reissued a “hold” rating on shares of Sage Therapeutics in a research note on Wednesday. Citigroup began coverage on shares of Sage Therapeutics in a research report on Wednesday, May 29th. They set a “sell” rating and a $8.00 price objective on the stock. Finally, JPMorgan Chase & Co. downgraded shares of Sage Therapeutics from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $18.00 to $12.00 in a report on Thursday. Two investment analysts have rated the stock with a sell rating, seventeen have issued a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $33.55.

Sage Therapeutics Trading Up 5.0 %

Shares of SAGE stock traded up $0.52 on Friday, reaching $10.99. The company’s stock had a trading volume of 930,739 shares, compared to its average volume of 988,437. The stock’s fifty day simple moving average is $11.28 and its 200-day simple moving average is $16.76. Sage Therapeutics, Inc. has a 1 year low of $9.73 and a 1 year high of $37.17. The company has a market capitalization of $661.40 million, a price-to-earnings ratio of -1.31 and a beta of 0.90.

Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.80) EPS for the quarter, missing analysts’ consensus estimates of ($1.63) by ($0.17). The business had revenue of $7.90 million during the quarter, compared to analysts’ expectations of $5.26 million. Sage Therapeutics had a negative return on equity of 56.81% and a negative net margin of 552.52%. The business’s quarterly revenue was up 139.4% on a year-over-year basis. During the same period in the previous year, the business earned ($2.46) earnings per share. Equities research analysts forecast that Sage Therapeutics, Inc. will post -6.65 earnings per share for the current year.

Sage Therapeutics Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.